STEMCELL Technologies Acquires Propagenix Inc.
January 19, 2024
STEMCELL Technologies, Canada’s largest biotechnology company, acquired Propagenix Inc., a Gaithersburg, Maryland biotechnology firm focused on epithelial cell biology and its patented EpiX technology. The acquisition includes Propagenix’s assets, IP (including its Conditional Reprogramming license with Georgetown University) and existing business arrangements, enabling STEMCELL to develop EpiX-based products for clinical applications and expand its regenerative-medicine capabilities.
- Buyers
- STEMCELL Technologies
- Targets
- Propagenix Inc.
- Sellers
- Propagenix co-founders
- Industry
- Biotechnology
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Axol Bioscience Acquires Phenocell
October 21, 2024
Biotechnology
Axol Bioscience Ltd. has fully acquired Phenocell SAS, adding Phenocell’s iPSC-derived skin and retinal cell lines and custom bioassay services to Axol’s drug discovery product portfolio. The acquisition expands Axol’s capabilities into ophthalmology and dermatology (including AMD and cosmetics testing); financial terms were not disclosed.
-
Great Point Partners Makes Growth Investment in iXCells Biotechnologies
September 29, 2022
Biotechnology
Great Point Partners, a Greenwich, CT-based healthcare-focused private investment firm, has made a growth investment in San Diego-based iXCells Biotechnologies. The capital will be used to expand iXCells' operational capacity, broaden its product and service offering (including bioanalytical capabilities) and support growth into adjacent high-growth end markets such as personalized medicine and rare disease research.
-
StemBioSys Acquires Majority Stake in Cartox
January 8, 2020
Biotechnology
San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.
-
Cancer Genetics (Vyant Bio) Acquires StemoniX
March 31, 2021
Biotechnology
Cancer Genetics, Inc. completed a merger with StemoniX, Inc. and renamed the combined company Vyant Bio, Inc., with the new ticker VYNT on Nasdaq. StemoniX will operate as a wholly-owned subsidiary as the combined business integrates human iPSC-derived biology, software and preclinical capabilities to create a unified drug discovery platform.
-
QHP Capital Acquires Applied StemCell
October 9, 2023
Biotechnology
QHP Capital has acquired Applied StemCell, a Milpitas, California–based cell and gene therapy CRO/CDMO that provides iPSC and TARGATT gene‑editing platforms for biopharma and research clients. QHP said the acquisition will provide strategic capital and operating support to accelerate ASC's commercial expansion and scale its manufacturing and service capabilities for the cell and gene therapy market.
-
Axol Bioscience Acquires Newcells Biotech's Ophthalmology Business
February 23, 2026
Biotechnology
Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, including its specialist team, facilities, and intellectual property for iPSC-derived retinal organoid and retinal pigment epithelium models. The deal expands Axol's ophthalmology capabilities and product portfolio to support biopharma, biotech and CRO customers across Europe and the United States, strengthening its position in ophthalmology drug discovery and safety testing.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.